NASDAQ: AKTXAkari Therapeutics PLC Stock
$10.25+0.00 (+0%)
Updated Jul 1, 2026
AKTX Price
$10.25
Fair Value Price
N/A
Market Cap
$0.00
52 Week Low
$3.02
52 Week High
$49.60
P/E
N/A
P/B
0x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$28.05M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.36
Operating Cash Flow
-$11M
Beta
0.6
Next Earnings
Aug 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AKTX Overview
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKTX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AKTX
Ranked#403 of 465
Ranked#403 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $237.51 | A | |
| $11.00 | A | |
| $15.80 | A |
Be the first to know about important AKTX news, forecast changes, insider trades & much more!
AKTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKTX's cash and short-term investments ($2.83M) cannot cover AKTX's cash burn for the next year (N/A), even if decreasing cash burn (N/A) is accounted for
Interest Coverage Financials
AKTX's short-term liabilities ($13.42M) exceed its short-term assets ($3.59M)
Short-term Liabilities Financials
AKTX's long-term liabilities ($6.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more AKTX due diligence checks available for Premium users.
Valuation
AKTX fair value
Fair Value of AKTX stock based on Discounted Cash Flow (DCF)
Price
$10.25
Fair Value
$5.29
Overvalued by
93.90%
AKTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0x
Industry
5.43x
AKTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.5M
Profit Margin
0%
AKTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$33.9M
Liabilities
$19.5M
Debt to equity
1.36
AKTX's short-term liabilities ($13.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTX's long-term liabilities ($6.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
$0.0
Financing
$53.0k
AKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKTX vs Biotech Stocks
Akari Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.